[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-and-joint-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-and-joint-infection":161},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,78,108,137],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100614820",false,"NCT07284563","Ultralow Dose PET Imaging for 18F-NaF Uptake","Evaluation of Ultralow Dose PET Imaging for Detecting 18F-NaF Uptake","Inclusion Criteria:\n\n* Age ≥18 years.\n* Ability to provide informed consent and comply with study procedures.\n* For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential.\n\nExclusion Criteria:\n\n* Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert \\[mSv\\] total).\n* More than four prior enrollments in this study.\n* Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan\n* Medication \\& Prior Treatment Exclusions\n* Concurrent treatments that may interfere with radiotracer uptake as determined by the Principle Investigator.\n* Pregnant or breastfeeding individuals (negative pregnancy test required)\n* Inability to provide informed consent\n* Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.",true,"ALL","18 Years","120 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET imaging) technique for increased bone turnover that is found in diseases such as cancer, trauma, infection, arthritis, and other benign diseases of bone detection and monitoring. The main question it aims to answer is:\n\nCan the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-sodium fluoride (NaF) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours.",[27,28,29,30,31],"Healthy Volunteer","Bone Alteration","Bone and Joint Cancer","Bone and Joint Infection","Arthritis",[33,34,35,36,37,38],"PET","PET\u002FCT","low dose","nuclear imaging","sodium fluoride","bone","RECRUITING","2025-12-08",{"date":42,"type":43},"2025-12-16","ACTUAL",{"date":45,"type":43},"2025-09-01",{"date":47,"type":21},"2030-06-30",{"name":49,"class":50},"Akiva Mintz","OTHER",2,{"id":53,"slug":4,"hasResults":10,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":10,"sex":16,"minAge":58,"maxAge":17,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100403801","NCT04538053","BonE and Joint Infections - Simplifying Treatment in Children Trial","BEST","Inclusion Criteria:\n\n* Children aged 1 to 18 years with acute, uncomplicated, community-acquired bone and joint infection who fulfil pre-defined clinical criteria.\n\nExclusion Criteria:\n\n1. Infection due to bacteria resistant to cefalexin or atypical infection (e.g. mycobacterial, fungal)\n2. Features of sepsis as defined by the presence of organ dysfunction (defined using definitions within the Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score)\n3. Concomitant severe, invasive infection e.g. necrosing fasciitis\n4. Complicated infection (e.g. presence of prosthetic material; large subperiosteal (\\>3mm) or soft tissue abscess without surgical intervention; infection secondary to or complicated by trauma)\n5. History of allergy to cephalosporin antibiotics or immediate, severe reaction to penicillins\n6. Received more than three IV or oral dose of an antibiotic with activity against the likely bacteria causing the current infection\n7. Prior episode of OM or SA\n8. Prior condition predisposing to poor absorption (e.g. inflammatory bowel disease, current gastrointestinal symptoms) or complicated disease (e.g. immunodeficiency)\n9. Prior enrolment in the trial\n10. Current recipient of another investigational product as part of a clinical trial","1 Year",{"count":60,"type":21},285,[62],"PHASE4","This is a multi- centre trial of children with bone and joint infections (BJIs) at eight major paediatric hospitals in Australia and New Zealand. The primary objective is to establish if in children with acute, uncomplicated BJIs, entirely oral antibiotic treatment is not inferior to initial intravenous (IV) treatment for 1 to 7 days followed by an oral antibiotic course in achieving full recovery 3 months after presentation. Children will be randomly allocated to the 'entirely oral antibiotic' group or the 'standard treatment' group.",[65,66,30,67],"Bone Infection","Septic Arthritis","Osteomyelitis","2025-11-14",{"date":70,"type":43},"2025-11-17",{"date":72,"type":43},"2021-06-01",{"date":74,"type":21},"2026-12",{"name":76,"class":50},"Murdoch Childrens Research Institute",10,{"id":79,"slug":4,"hasResults":10,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":10,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100400575","NCT04496024","Ofloxacin Concentration-toxicity Relationship in the Elderly","Determination of a Trough Serum Concentration of Ofloxacin Associated to Increase in Side Effects Frequency in Elderly Treated for Bone and Joint Infection","ROSCO","Inclusion Criteria:\n\n* Patients aged over 65 years hospitalized at the University Hospital of Amiens for an uncomplicated bone and joint infections\n* Indication for oral switch to ofloxacin\n\nExclusion Criteria:\n\n* Patient refusing to participate in the study\n* Patient under guardianship or curators or deprived of public rights\n* Any liver or biliary injury\n* Any contraindications to ofloxacin","65 Years",{"count":87,"type":21},110,[89],"NA","Ofloxacin is a gold standard antibiotic for the treatment of bone and joint infections due to sensible staphylococcus strains. However, in the elderly, inter-individual variability of the pharmacokinetics may reduce the efficacy or increase toxicity. The occurrence of ofloxacin side effects is likely to be increased in case of higher exposition. However, the serum concentration-toxicity relationship has not yet been determined. The purpose of this project is to assess the association between the residual serum concentration of ofloxacin at day 3 and the occurrence of at least one adverse effect attributable to ofloxacin, and determine a threshold toxicity concentration if this association exists.",[92,30,93,94],"Ofloxacin","Therapeutic Drug Monitoring","Adverse Drug Reactions",[96,30,97,94],"ofloxacin","therapeutic drug monitoring","2025-06-05",{"date":100,"type":43},"2025-06-10",{"date":102,"type":43},"2020-06-02",{"date":104,"type":21},"2026-08",{"name":106,"class":50},"Centre Hospitalier Universitaire, Amiens",1,{"id":109,"slug":4,"hasResults":10,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":10,"sex":16,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":118,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":107},"100579684","NCT06827496","Initial Oral Antibiotics for Bone and Joint Infections in Children","Initial Oral Antibiotics for Bone and Joint Infections in Children: A Prospective Nationwide Real-world Effectiveness Study in Denmark","Children and adolescents aged 3 months to 17 years with uncomplicated bone and joint infections treated with initial oral antibiotics.\n\nAccording to Danish Nationwide Guidelines (initiated in 2024), initial oral antibiotics are recommended to patients with no risk factors for complicated disease. Risk factors include for complicated disease include:\n\n1. Severe illness or sepsis\n2. Rapid symptom progression\n3. Pronounced symptoms, including severe pain\n4. Pronounced soft tissue involvement\n5. Foreign material or post-surgical infection\n6. Infection with a resistent or rare pathogen, e.g., Salmonella or MRSA\n7. Severe comorbidity, including immunodeficiency\n\nPatients who have received intravenous antibiotic therapy for less than 24 h before oral antibiotics will be included","3 Months","17 Years",{"count":117,"type":21},100,"5 Years","OBSERVATIONAL","Initial oral antibiotic treatment for children and adolescents with uncomplicated bone and joint infections (BJI) has been found non-inferior to initial IV antibiotics in one randomized controlled trial (RCT). The real-world effectiveness of initial oral antibiotics for children and adolescents with BJI is unclear.\n\nThis nationwide, prospective, multicenter, real-world cohort study aims to compare the effectiveness and safety of initial oral antibiotic treatment for children and adolescents with uncomplicated BJI in a real-world setting with those who received initial oral antibiotics in our RCT.",[122,66,65,123,30],"Osteomyelitis Acute","Joint Infection",[125,126,127,67],"Bone and joint infections","Children","Oral antibiotics","2025-04-05",{"date":130,"type":43},"2025-04-09",{"date":132,"type":43},"2024-11-15",{"date":134,"type":21},"2027-05",{"name":136,"class":50},"Rigshospitalet, Denmark",{"id":138,"slug":4,"hasResults":10,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":10,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":107},"100418122","NCT04724603","Phage Safety Retrospective Cohort Study","PHASACO-retro","Inclusion Criteria:\n\n* patients having had a bone or joint or implant infection treated by phagotherapy and having had an adverse event\n\nExclusion Criteria:\n\n\\-",{"count":144,"type":21},25,"The aim of this study is to determine the imputability of adverse events in patients who have had phage therapy for the treatment of their bone or joint or implant infection, in order to find out whether these adverse effects are related to surgery, antibiotic treatment or bacteriophages.",[30,147],"Prosthetic Joint Infection",[149,150,151,147],"bone and joint infection","phagotherapy","adverse event","2023-04-12",{"date":154,"type":43},"2023-04-13",{"date":156,"type":43},"2021-02-01",{"date":158,"type":21},"2026-09-01",{"name":160,"class":50},"Hospices Civils de Lyon",""]